All In Biotech

Drug Trial Radar · NCT05730283

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Jun 2, 2025

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Kevin WinthropAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD); National Center for Advancing Translational Sciences (NCATS); Oricula Therapeutics; University of Washington; National Jewish Health; Mayo Clinic; The University of Texas Health Science Center at Tyler; Medical University of South Carolina; University of California, San Francisco; Johns Hopkins University; Northwell Health
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is: * Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? * Is ORC-13661 effective for preventing or lessening other measures of hearing impairment? Participants will be asked to take a study drug while they are being treated with IV amikacin. Participants will take study drug for 90 days or until the end of their amikacin treatment, whichever comes first. During this time, researchers will gather clinical data on the participants' health. Researchers will compare three groups - two groups taking different doses of the study drug and one group taking a placebo drug - to see if dose of drug has any effect on preventing hearing loss. A placebo is a look-alike substance that contains no active drug.

Conditions

  • Ototoxicity, Drug-Induced

Interventions

  • ORC-13661Drug

    High-dose intervention (30mg daily)

  • ORC-13661Drug

    Low-dose intervention (12mg daily)

  • PlaceboDrug

    Placebo intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mitigation or Prevention of OtotoxicityTime frame: Baseline to 28 (±5) days after study treatment discontinuation or 28 days after 90 days of study treatment, whichever comes first.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • National Jewish Health

    Denver, Colorado · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Withdrawn

  • Northwell Health

    Manhasset, New York · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • University of Texas Health Science Center

    Tyler, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.